



## SUGGESTED FORMULA

\_\_\_\_\_

## **Chlorothiazide 50mg/mL Oral Suspension**

Version number: 1.0 Volume: 100mL

\_\_\_\_\_\_

Chlorothiazide 500mg Tablets #10 Tablets
Liquid Flavor (Optional) 1.6mL
Sodium Carboxymethylcellulose , USP (CA192) 2gm
Glycerin, USP (G1016) 10mL

Propylparaben, NF (PR133) 0.05gm (0.05%) Methylparaben, NF (ME163) 0.05gm (0.05%)

Citric Acid Monohydrate, USP (CI132) pH4 (Approximately 800mg needed)

Purified Water, USP (W1014) 100mL Q.S.

\_\_\_\_\_

Note: This formula is usually available as a commercial product. Do not compound unless it has been verified that the product is currently on the FDA Drug Shortage List.

## SUGGESTED COMPOUNDING PROCEDURES

- 1. Count out tablets and crush until fine powder in Ceramic Mortar and Pestle
- 2. Weigh all powder ingredients (Except Citric Acid) and combine with step 1
- 3. Dry triturate to break down any remaining clumps
- 4. Add enough Glycerin into mortar and pestle to form a "paste"
- 5. Triturate until all Chemicals are broken down and incorporated into Glycerin
- 6. Add more liquid until pourable mixture and pour into calibrated final container
- 7 Perform liquid "washes" in mortar and pestle to integrate remaining chemical
- 8. Pour each "wash" into final container taking precaution not to go over the final volume
- 9. Q.S. medication and shake well.
- 10. Add small amount of Citric Acid until final pH 4.0
- 11. Suggested Quality Assessments follow pharmacy SOPs:
  - a. Weight to Volume calculation
  - b. Color
  - c. Pourability
  - d. Settling
  - e. Resuspendability

Store in air tight amber plastic containers Store Refrigerated

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

**Beyond-Use Date is estimated to be** <u>30 Days</u> Per *Trissel's Stability of Compounded Formulations 5<sup>th</sup> Edition* 

Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate protective equipment. Use safety enclosures (hoods) when weighing and mixing.

Although much attention has been paid to ensure the accuracy of the formulation contained here, Spectrum Pharmacy Products accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold Spectrum Pharmacy Products and Spectrum Chemical Mfg Corp. and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein. 06/15 JD

Phone: 800.370.6231 | Fax: 732.608.5420 | Internet: SpectrumRx.com | Email: sales@spectrumrx.com 
© 2015 Spectrum Pharmacy Products. All rights reserved.